Choose Your Country or Region

Gedatolisib (PKI-587)

Name: Gedatolisib (PKI-587)
Brand: Selleck Chemicals
SKU: S2628
Rating: 5 (19 reviews)

Catalog No.S2628 Synonyms: PF-05212384

For research use only.

Gedatolisib (PF-05212384, PKI-587) is a highly potent dual inhibitor of PI3Kα, PI3Kγ and mTOR with IC50 of 0.4 nM, 5.4 nM and 1.6 nM in cell-free assays, respectively. Phase 2.

Gedatolisib (PKI-587) Chemical Structure

CAS No. 1197160-78-3

Selleck's Gedatolisib (PKI-587) has been cited by 19 publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Related Compound Libraries

Other PI3K Products

Taselisib (GDC 0032)^New

Taselisib (GDC 0032, RG7604) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with K_i of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.
Pilaralisib (XL147)^New

Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.
LY294002

LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.
Idelalisib

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR. Idelalisib also stimulates autophagy.
Wortmannin (KY 12420)

Wortmannin (KY 12420, SL-2052, BRN 0067676, NSC 627609) is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Wortmannin blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays. Wortmannin also inhibits PLK1 activity.
Dactolisib (BEZ235)

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell. Dactolisib induces autophagy and suppresses HIV-1 replication. Phase 2.
Buparlisib (BKM120)

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Buparlisib induces apoptosis. Phase 2.
Pictilisib (GDC-0941)

Pictilisib (GDC-0941, RG7321) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Pictilisib (GDC-0941) induces autophagy and apoptosis. Phase 2.

Download Inhibitor Catalog

PI3K Signaling Pathway Map

Biological Activity

Description

Gedatolisib (PF-05212384, PKI-587) is a highly potent dual inhibitor of PI3Kα, PI3Kγ and mTOR with IC50 of 0.4 nM, 5.4 nM and 1.6 nM in cell-free assays, respectively. Phase 2.

Targets

PI3Kα ^[1] (Cell-free assay)	mTOR ^[1] (Cell-free assay)	PI3Kγ ^[1] (Cell-free assay)
0.4 nM	1.6 nM	5.4 nM

In vitro

PKI-587 shows potent inhibitory activity against PI3K-α, PI3K-γ and mTOR with IC50 of 0.4 nM, 5.4 nM and 1.6 nM, respectively. Furthermore, PKI-587 also exhibits its potency against the most frequently occurring mutant forms of PI3Kα, notably the H1047R and E545K with IC50 of 0.6 nM and 0.6 nM, respectively. ^[1] Correlated with suppression of phosphorylation of PI3K/mTOR signaling pathway proteins, PKI-587 causes tumor cell growth inhibition in MDA-361 and PC3-MM2 cell lines with IC50 of 4 nM and 13.1 nM, respectively. ^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

MDA-MB-361 cells	M{DqRmN6fG:2b4jpZ4l1gSCjc4PhfS=>		M3;5fWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2zOlEh[2WubIOsJGlEPTB;MD6wNFQh\|ryP	NHHqTnozODF4Nk[5Oy=>
PC3MM2 cells	NEnxU2tEgXSxdH;4bYNqfHliYYPzZZk>		MXrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQR\|NOVTJiY3XscJMtKEmFNUC9NE4xOTNzIN88US=>	NHjwSo0zODF4Nk[5Oy=>
MDA-MB-361 cells	MkHLSpVv[3Srb36gZZN{[Xl?		MnPPTY5pcWKrdHnvckBw\iCDa4SgWFMxQCCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hVUSDLV3CMVM3OSClZXzsd{BjgSCZZYP0[ZJvKGKub4T0bY5oNCCLQ{WwQVAvODB6IN88US=>	M4rZTVIxOTZ4Nkm3
MDA-MB-361 cells	NUnre\|V6TnWwY4Tpc44h[XO\|YYm=		NXPCcGRwUW6qaXLpeIlwdiCxZjDBb5QhWzR5MzDwbI9{eGixconsZZRqd25iaX6gbJVu[W5iTVTBMW1DNTN4MTDj[YxteyCkeTDX[ZN1\XKwIHLsc5R1cW6pLDDJR\|UxRTBwMEGg{txO	NWroSGk5OjBzNk[2PVc>
MDA-MB-361 cells	NHzvbllHfW6ldHnvckBie3OjeR?=		MULJcohq[mm2aX;uJI9nKGWQT2OgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIF3ERU1OSi1\|NkGgZ4VtdHNiYomgW4V{fGW{bjDicI91fGmwZx?=	NYPneFc1OjBzNk[2PVc>
MDA-MB-361 cells	MVvGeY5kfGmxbjDhd5NigQ>?		M4f0XGlvcGmkaYTpc44hd2ZiUFHSV\|QxKHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBOTEFvTVKtN\|YyKGOnbHzzJIJ6KFenc4Tldo4h[myxdITpcoc>	M2\LTlIxOTZ4Nkm3
MDA-MB-361 cells	MnuwSpVv[3Srb36gZZN{[Xl?		NVGycFF2UW6qaXLpeIlwdiCxZjDHV2s{KGurbnHz[UBxcG:\|cHjvdplt[XSrb36gbY4hcHWvYX6gUWRCNU2ELUO2NUBk\WyuczDifUBY\XO2ZYLuJIJtd3S2aX7n	MkDCNlAyPjZ4OUe=
MDA-MB-361 cells	M33iV2Z2dmO2aX;uJIF{e2G7		MVHJcohq[mm2aX;uJI9nKG2WT2KgWG9TSzFia3nuZZNmKGGldHn2bZR6KGmwIHj1cYFvKE2GQT3NRk0{PjFiY3XscJMh[XO\|ZYPz[YQh[XNic4XwdJJme3Orb36gc4YheDdyU{\LJJBpd3OyaH;yfYxifGmxbjDheEA9KDNyIH7N	MUGyNFE3PjZ7Nx?=
MDA-MB-361 cells	Ml7vSpVv[3Srb36gZZN{[Xl?		MnjuTY5pcWKrdHnvckBw\iCvVF;SJHRQWkNzIHvpcoF{\SCjY4Tpeol1gSCrbjDoeY1idiCPRFGtUWIuOzZzIHPlcIx{KGG\|c3Xzd4VlKGG\|IIP1dJBz\XO\|aX;uJI9nKDSHQmCxJJBpd3OyaH;yfYxifGmxbjDheEA9KDNyIH7N	NWSyWm55OjBzNk[2PVc>
MDA-MB-361 cells	MoHrSpVv[3Srb36gZZN{[Xl?		Mn7JTY5pcWKrdHnvckBw\iCDa4SgWFMxQCCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hVUSDLV3CMVM3OSClZXzsd{B5\W6xZ4Lh[pRm\CCvb4Xz[UBud2SnbDD1dJRwKDN4IHjydy=>	NVrPeJZ2OjBzNk[2PVc>
MDA-MB-361 cells	M37mXWZ2dmO2aX;uJIF{e2G7		NHq2WHhKdmirYnn0bY9vKG:oIFHreEBUPDd\|IIDoc5NxcG:{eXzheIlwdiCrbjDoeY1idiCPRFGtUWIuOzZzIHPlcIx{KHinbn;ndoFnfGWmIH3veZNmKG2xZHXsJJVxfG9iM{[gbJJ{	MWqyNFE3PjZ7Nx?=
MDA-MB-361 cells	Mkn6SpVv[3Srb36gZZN{[Xl?		MYXJcoR2[3Srb36gc4YhWEGUUDDjcIVifmGpZTDpckBpfW2jbjDNSGEuVUJvM{[xJINmdGy\|IIjlco9oemGodHXkJI1wfXOnIH3v[IVtKHWydH:gNVghcHK\|	Mn31NlAyPjZ4OUe=
MDA-MB-361 cells	NX7lWFNFTnWwY4Tpc44h[XO\|YYm=		MYLBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPRFGtUWIuOzZzIHPlcIx{KHinbn;ndoFnfGWmIH3veZNmKG2xZHXsJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjD0eY1weiC4b3z1cYUh[XRiMkCgcYcwc2duIHn2JI9vKGSjeTCxMEA2NCB7	MXeyNFE3PjZ7Nx?=
SF9 insect cells	NYfETHVTTnWwY4Tpc44h[XO\|YYm=	MWiyJIg>	MnzpTY5pcWKrdHnvckBw\iCqdX3hckBRUTONYXzwbIEh\XiycnXzd4VlKGmwIGPGPUBqdnOnY4SgZ4VtdHNiYX\0[ZIhOiCqcoOgZpkh\my3b4Lld4NmdmOnIIDvcIFzcXqjdHnvckBie3OjeTygTWM2OD1yLkCwNFQh\|ryP	NHvkdnQzOTd4M{GzOC=>
SF9 insect cells	M2TyVmZ2dmO2aX;uJIF{e2G7	MmnZNkBp	MXvJcohq[mm2aX;uJI9nKGi3bXHuJHBKO0upYX3tZUBmgHC{ZYPz[YQhcW5iU1[5JIlve2WldDDj[YxteyCjZoTldkAzKGi{czDifUBndHWxcnXzZ4Vv[2VicH;sZZJqgmG2aX;uJIF{e2G7LDDJR\|UxRTBwMEGx{txO	MXKyNVc3OzF\|NB?=
MDA-MB-361 cells	NIDKdpdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M4n1SVczKGh?	Ml63S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUWRCNU2ELUO2NUBk\WyuczDh[pRmeiB5MjDodpMtKEmFNUC9NE4xODNizszN	NXzRWFd4OjF5NkOxN\|Q>
human PC3 cells	MmCyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M3q1RlczKGh?	MWjHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDQR\|Mh[2WubIOgZYZ1\XJiN{KgbJJ{NCCLQ{WwQVAvODFzIN88US=>	NHu0Z2MzOTd4M{GzOC=>

Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID

Growth inhibition assay	Cell viability	29978469
Western blot	p-AKT / p-mTOR / p-p70S6K / p-S6K / p-4E-BP1 / AKT / mTOR / p70S6K / S6K / 4EBP1 ; TSC1 / TSC2 / Raptor	29978469

In vivo

In nude mice, PKI-587 treatment at 25 mg/kg iv leads to low plasma clearance (7 (mL/min)/kg), high volume of distribution (7.2 L/kg), and long half-life, (14.4 hours). In the MDA-361 xenograft model, PKI-587 produces potent antitumor efficacy with the minimum efficacious dose (MED) of 3 mg/kg against MDA-361 tumors and maximum tolerated single dose (MTD) of 30 mg/kg. While in the H1975 (non-small-cell lung carcinoma, mutant EGFR [L858R, T790M]) xenograft model, PKI-587 at 25 mg/kg for 7 weeks results in 90% survival of the group treated. ^[1]

Protocol (from reference)

Kinase Assay:^[1]	PI3K and mTOR kinase assay : Enzyme assays are done in fluorescent polarization (FP) format, adapted from the Echelon K-1100 PI3K FP assay kit protocol. Human class I PI3Ks and PI3K-α mutants (E545K and H1047R) are produced in Sf9 or purchased from Upstate Biotech. GST-GRP1 (murine) is produced in Escherichia coli and isolated by GST-Sepharose. Assay buffers are reaction buffer [20 mM HEPES (pH 7.1), 2 mM MgCl₂, 0.05% CHAPS, and 0.01% β-mercaptoethanol] and stop/detection buffer [100 mM HEPES (pH 7.5), 4 mM EDTA, 0.05% CHAPS]. FP reaction is run for 30 minutes at room temperature in 20 μL of reaction buffer containing 20 μM phosphatidylinositol 4,5-bisphosphate (PIP2), 25 μM ATP, and <4% DMSO. FP reaction is stopped with 20 μL of stop/detection buffer (10 nM probe and 40 nM GST-GRP), and after 2 hours, data are collected using an Envision plate reader. The routine assays with purified FLAG-TOR (FL and 3.5) are performed in 96-well plates as follows. Enzymes are first diluted in kinase assay buffer (10 mM Hepes (pH 7.4), 50 mM NaCl, 50 mM β-glycerophosphate, 10 mM MnCl₂, 0.5 mM DTT, 0.25 μM microcystin LR, and 100 μg/mL BSA). To each well, 12 μL of the diluted enzyme is mixed briefly with 0.5 μL test inhibitor or control vehicle dimethyl sulfoxide (DMSO). The kinase reaction is initiated by adding 12.5 μL kinase assay buffer containing ATP and His6-S6K to give a final reaction volume of 25 μL containing 800 ng/mL FLAG-TOR, 100 μM ATP, and 1.25 μM His6-S6K. The reaction plate is incubated for 2 hours (linear at 1–6 hours) at room temperature with gentle shaking and then terminated by adding 25 μL Stop buffer (20 mM Hepes (pH 7.4), 20 mM EDTA, and 20 mM EGTA).
Cell Research:^[1]	Cell lines: MDA-361 and PC3-MM2 Concentrations: 0-10 μM Incubation Time: 72 hours Method: Cells are plated in 96-well culture plates at about 3000 cells per well. One day following plating, PKI-587 is added to cells. Three days after PKI-587 treatment, viable cell densities are determined by measuring metabolic conversion (by viable cells) of the dye MTS, a previously established cell proliferation assay. For each assay, MTS and PMS stocks are freshly thawed and mixed (MTS/PMS, 20:1). The MTS/PMS mixture is then added to 96-well cell plates at 20 μL/well, and plates are incubated for 1 hour–2 hours in cell culture incubator. MTS assay results are read in a 96-well format plate reader by measuring absorbance at 490 nm. The effect of each PKI-587 treatment is calculated as a percentage of control cell growth obtained from vehicle-treated cells grown in the same culture plate.
Animal Research:^[1]	Animal Models: MDA-361 and H1975 cells are injected subcutaneously into the nude mice. Dosages: ≤30 mg/kg Administration: Administered via i.v.

References

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight	615.73
Formula	C₃₂H₄₁N₉O₄
CAS No.	1197160-78-3
Storage	3 years	-20°C	powder
Storage	2 years	-80°C	in solvent
Smiles	CN(C)C1CCN(CC1)C(=O)C2=CC=C(C=C2)NC(=O)NC3=CC=C(C=C3)C4=NC(=NC(=N4)N5CCOCC5)N6CCOCC6

Download Gedatolisib (PKI-587) SDF

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

Clinical Trial Information

NCT Number	Recruitment	Interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02438761	Terminated	Drug: PF-05212384	Therapy-related Acute Myeloid Leukemia and Myelodysplastic Syndrome\|Acute Myeloid Leukemia in Relapse\|de Novo Acute Myeloid Leukemia at Diagnostic	Institut Curie\|Fondation ARC\|National Cancer Institute France	August 31 2015	Phase 2
NCT02069158	Completed	Drug: PF-05212384\|Drug: Paclitaxel\|Drug: Carboplatin	Breast Cancer\|NSCLC\|Ovary Cancer\|Endometrial Cancer\|Small Cell Lung Cancer (SCLC)\|Head and Neck (HNSCC)	Cristiana Sessa\|Oncology Institute of Southern Switzerland	April 2014	Phase 1
NCT01420081	Terminated	Drug: PF-05212384	Endometrial Neoplasms	Pfizer	January 19 2012	Phase 2

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):